Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8525810 | Biomedicine & Pharmacotherapy | 2018 | 7 Pages |
Abstract
Despite the reported reduction in blood pressure in hypertensive patients treated with allopurinol, the mechanism of the allopurinol hypotensive effect is still unclear. In the current study, the hypotensive effect of allopurinol has been fully investigated in hypertensive rats. Hypertension was induced in rats by angiotensin II (120â¯ng/min/kg) infusion for two weeks. Rats were then subjected to real-time recording of blood pressure, left ventricular pressure and volume and surface ECG. After 10â¯min of basal recording, allopurinol was slowly injected into the femoral vein with a dose of 10â¯Î¼mole/kg. Then, invasive blood pressure, cardiac hemodynamics and ECG were continuously recorded for an additional 20â¯min. In addition, the vasodilation effect of allopurinol was studied using the isolated artery technique. Allopurinol injection reduced systolic, diastolic and pulse blood pressure. Allopurinol suppressed both cardiac systolic and diastolic hemodynamics as is apparent from the reduction in the rate of rise and the rate of fall in left ventricular pressure. Allopurinol reduced the general cardiac output quickly. Allopurinol addition to the organ bath (10-1000â¯Î¼M) produced significant vasodilation of PE pre-constricted aortae that was not affected by endothelium denudation, L-NAME or indomethacin. However, allopurinol ameliorated the calcium induced contraction of aorta pre-constricted with KCl in calcium-free media. Erk or ROCK inhibition did not attenuated allopurinol produced vasodilation. In conclusion, allopurinol has an antihypertensive effect that is mediated, probably, by reducing cardiac output and decreasing vascular resistance. The vasodilator effect of allopurinol is most likely mediated by calcium blocking activities.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Hany M. El-Bassossy, Mona F Mahmoud, Basma G Eid,